Effect of NMSO3 treatment in a murine model of human metapneumovirus infection.
BALB/c mice infected with human metapneumovirus (hMPV) were treated with the sulfated sialyl lipid NMSO3 (one dose of 50 mg kg(-1)) given at the time of infection. NMSO3 significantly reduced viral replication in the lungs, as well as hMPV-induced body weight loss, pulmonary inflammation and cytokine production, suggesting that antiviral treatment initiated at the beginning of viral infection can modify hMPV-induced disease.
Spetch
Leanne
L
Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA.
Bowlin
Terry L
TL
Microbiotix Inc., Worcester, MA, USA.
Casola
Antonella
A
Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA.|Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.|Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA.
D000818:Animals; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007249:Inflammation / Q000139:chemically induced; D008055:Lipids / Q000009:adverse effects / Q000627:therapeutic use*; D008168:Lung / Q000821:virology; D008171:Lung Diseases / Q000139:chemically induced / Q000503:physiopathology; D029121:Metapneumovirus / Q000187:drug effects* / Q000502:physiology; D051379:Mice; D008807:Mice, Inbred BALB C; D019158:N-Acetylneuraminic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018184:Paramyxoviridae Infections / Q000188:drug therapy*; D014779:Virus Replication / Q000187:drug effects; D015431:Weight Loss / Q000187:drug effects
C413863:(2,2-bis(docosyloxymethyl)propyl-5-acetamido-3,5-dideoxy-4,7,8,9-tetra-O-(sodium oxysulfonyl)glycero-alpha-galacto-2-nonulopyranosid)onate; D016207:Cytokines; D008055:Lipids; D019158:N-Acetylneuraminic Acid